Status:
NOT_YET_RECRUITING
CME Versus Standard Right Hemicolectomy for Right Sided Cancers
Lead Sponsor:
Odense University Hospital
Conditions:
Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Our aim of this study is to compare the difference in lymph node yield in CME specimens versus those patients having a standard right hemicolectomy for right sided cancer .The secondary aim of this st...
Detailed Description
CRC is the third most common cancer in men and second most common in women with almost 55% of these cases occurring in more developed nations Findings from a recent population-based study showed that ...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the trial.
- Male or Female, aged 18 years or above.
- Undergoing CME or standard right hemicolectomy surgery for right-sided cancer after MDT discussion.
- Cancer must be confirmed by histological, radiological, endoscopic diagnosis
- In the Investigator's opinion, is able and willing to comply with all trial requirements.
Exclusion
- Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
- Participant with life expectancy of less than 6 months.
- Distal Transverse colon and splenic flexure tumors
- Evidence of T4 disease invading adjacent organs
- Synchronous surgical procedure planned with CME or right hemicolectomy
- Urgent, unplanned or emergency surgery
- Neoadjuvant chemotherapy administered to treat this cancer prior to resection
- Concurrent or previous abdominal or pelvic malignancy within five years prior to registration irrespective of treatment modality
- Known Crohn's disease with active terminal ileal disease
- Evidence of systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude surgery, or other severe incapacitating disease, i.e. ASA IV (a patient with severe systemic disease that is a constant threat to life) or ASA V (a moribund patient who is not expected to survive without the operation).
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2028
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT05230329
Start Date
March 1 2022
End Date
February 1 2028
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Issam al-Najami
Svendborg, Southern Denmark, Denmark, 5700